Figure 2.
Kaplan–Meier survival analysis. Median overall survival for all patients (n = 13) was 5.6 months (95% CI 0.1–11.9) from start of pembrolizumab treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.